Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (81-90 of 189) with videos related to

Pageof 19
Sort By:
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
Clinical Epigenetics|October 5, 2018
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDsLaurie Herviou, Alboukadel Kassambara, Stéphanie Boireau, et al.
Frontiers in Immunology|August 7, 2018
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront ResistanceAnja Seckinger, Jens Hillengass, Martina Emde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculationJens Hillengass, Christian Zechmann, Tobias Bäuerle, et al.
Experimental Hematology|November 13, 2012
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myelomaIsabelle Herth, Mathias Witzens-Harig, Philipp Beckhove, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Experimental Hematology|March 30, 2006
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myelomaMichael Hundemer, Stefanie Schmidt, Maud Condomines, et al.
Blood|June 19, 2012
Clinical and prognostic role of annexin A2 in multiple myelomaAnja Seckinger, Tobias Meissner, Jérôme Moreaux, et al.
Pageof 19

Showing results (81-90 of 189) with videos related to

Sort By:
Pageof 19
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
Clinical Epigenetics|October 5, 2018
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDsLaurie Herviou, Alboukadel Kassambara, Stéphanie Boireau, et al.
Frontiers in Immunology|August 7, 2018
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront ResistanceAnja Seckinger, Jens Hillengass, Martina Emde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculationJens Hillengass, Christian Zechmann, Tobias Bäuerle, et al.
Experimental Hematology|November 13, 2012
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myelomaIsabelle Herth, Mathias Witzens-Harig, Philipp Beckhove, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Experimental Hematology|March 30, 2006
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myelomaMichael Hundemer, Stefanie Schmidt, Maud Condomines, et al.
Blood|June 19, 2012
Clinical and prognostic role of annexin A2 in multiple myelomaAnja Seckinger, Tobias Meissner, Jérôme Moreaux, et al.
Pageof 19